Please login to the form below

Not currently logged in
Email:
Password:

lixisenatide

This page shows the latest lixisenatide news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is

Latest news

More from news
Approximately 12 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics